The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.
first published: Mar 12, 2012 09:59 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

